BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30079458)

  • 1. Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen species.
    Flores-Lopez G; Moreno-Lorenzana D; Ayala-Sanchez M; Aviles-Vazquez S; Torres-Martinez H; Crooks PA; Guzman ML; Mayani H; Chávez-González A
    J Cell Mol Med; 2018 Oct; 22(10):4899-4912. PubMed ID: 30079458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.
    Guzman ML; Rossi RM; Karnischky L; Li X; Peterson DR; Howard DS; Jordan CT
    Blood; 2005 Jun; 105(11):4163-9. PubMed ID: 15687234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
    Moreno-Lorenzana D; Avilés-Vazquez S; Sandoval Esquivel MA; Alvarado-Moreno A; Ortiz-Navarrete V; Torres-Martínez H; Ayala-Sánchez M; Mayani H; Chavez-Gonzalez A
    Cell Cycle; 2016 May; 15(9):1276-87. PubMed ID: 26985855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin in combination with bergamottin potentiates TNF-induced apoptosis through modulation of NF-κB signalling pathway in human chronic myelogenous leukaemia.
    Kim SM; Lee EJ; Lee JH; Yang WM; Nam D; Lee JH; Lee SG; Um JY; Shim BS; Ahn KS
    Pharm Biol; 2016 Oct; 54(10):2050-60. PubMed ID: 26911804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal.
    Toofan P; Busch C; Morrison H; O'Brien S; Jørgensen H; Copland M; Wheadon H
    Cell Death Dis; 2018 Sep; 9(9):927. PubMed ID: 30206237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model.
    Nasr RR; Hmadi RA; El-Eit RM; Iskandarani AN; Jabbour MN; Zaatari GS; Mahon FX; Pisano CC; Darwiche ND
    Int J Cancer; 2015 Aug; 137(3):698-709. PubMed ID: 25557649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo.
    Mendonca MS; Turchan WT; Alpuche ME; Watson CN; Estabrook NC; Chin-Sinex H; Shapiro JB; Imasuen-Williams IE; Rangel G; Gilley DP; Huda N; Crooks PA; Shapiro RH
    Free Radic Biol Med; 2017 Nov; 112():318-326. PubMed ID: 28782644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species.
    Shanmugam R; Kusumanchi P; Cheng L; Crooks P; Neelakantan S; Matthews W; Nakshatri H; Sweeney CJ
    Prostate; 2010 Jul; 70(10):1074-86. PubMed ID: 20209491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells.
    Kim YR; Eom JI; Kim SJ; Jeung HK; Cheong JW; Kim JS; Min YH
    J Pharmacol Exp Ther; 2010 Nov; 335(2):389-400. PubMed ID: 20699435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species.
    Shanmugam R; Kusumanchi P; Appaiah H; Cheng L; Crooks P; Neelakantan S; Peat T; Klaunig J; Matthews W; Nakshatri H; Sweeney CJ
    Int J Cancer; 2011 May; 128(10):2481-94. PubMed ID: 20669221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer.
    D'Anneo A; Carlisi D; Lauricella M; Puleio R; Martinez R; Di Bella S; Di Marco P; Emanuele S; Di Fiore R; Guercio A; Vento R; Tesoriere G
    Cell Death Dis; 2013 Oct; 4(10):e891. PubMed ID: 24176849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.
    Antoszewska-Smith J; Pawlowska E; Blasiak J
    Acta Biochim Pol; 2017; 64(1):1-10. PubMed ID: 27904889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.
    Guzman ML; Rossi RM; Neelakantan S; Li X; Corbett CA; Hassane DC; Becker MW; Bennett JM; Sullivan E; Lachowicz JL; Vaughan A; Sweeney CJ; Matthews W; Carroll M; Liesveld JL; Crooks PA; Jordan CT
    Blood; 2007 Dec; 110(13):4427-35. PubMed ID: 17804695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
    Jin B; Wang C; Li J; Du X; Ding K; Pan J
    Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.
    Sánchez-Sánchez B; Gutiérrez-Herrero S; López-Ruano G; Prieto-Bermejo R; Romo-González M; Llanillo M; Pandiella A; Guerrero C; Miguel JF; Sánchez-Guijo F; Del Cañizo C; Hernández-Hernández A
    Clin Cancer Res; 2014 Aug; 20(15):4014-25. PubMed ID: 24833663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
    Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
    Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.